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Acid-sensing ion channel 1 (ASIC1) is a H-gated channel
of the amiloride-sensitive epithelial Na channel (ENaC)/de-
generin family. ASIC1 is expressed mostly in the central and
peripheral nervous system neurons. ENaC and ASIC function is
regulated by several serine proteases. The type II transmem-
brane serine protease matriptase activates the prototypical
ENaC channel, but we found thatmatriptase is expressed in
glioma cells and its expression is higher in glioma compared
with normal astrocytes. Therefore, the goal of this study was to
test the hypothesis that matriptase regulates ASIC1 function.
Matriptase decreased the acid-activated ASIC1 current as mea-
sured by two-electrode voltage clamp in Xenopus oocytes and
cleaved ASIC1 expressed in oocytes or CHO K1 cells. Inactive
S805A matriptase had no effect on either the current or the
cleavage of ASIC1. The effect of matriptase on ASIC1 was spe-
cific, because it did not affect the function of ASIC2 and no
matriptase-specific ASIC2 fragments were detected in oocytes
or in CHO cells. Three matriptase recognition sites were iden-
tified in ASIC1 (Arg-145, Lys-185, and Lys-384). Site-directed
mutagenesis of these sites prevented matriptase cleavage of
ASIC1. Our results show that matriptase is expressed in glioma
cells and that matriptase specifically cleaves ASIC1 in heterolo-
gous expression systems.
Acid-sensing ion channels (ASICs)2 are H-gated members
of the epithelial Na channel/degenerin (ENaC/Deg) family of
amiloride-sensitive ion channels (1). Thus far, four ASIC genes
have been cloned, ASIC1–ASIC4 (2). Human ASIC1 exists as
two isoforms, ASIC1a and ASIC1b, with hASIC1a containing
an extra 43 amino acids in the region just before the start of the
second transmembrane domain (3). The recent crystallization
of chicken ASIC1 has revealed that ASIC1 is likely to be a tri-
mer. EachASIC1 subunit consists of short intracellularN andC
termini, two transmembrane domains, and a large extracellular
loop, which inASICs contains the pH-sensing region (4). ASICs
are expressed mainly in the neurons of the central and periph-
eral nervous systems, where they are implicated in physiologi-
cal functions such as learning and memory and pathologies
such as neurodegenerative diseases and ischemia (1). ASIC1 is
also expressed in glioblastoma multiforme (GBM) cells, highly
invasive and proliferative primary brain tumors, where it plays
an important role in cell migration and proliferation (5–8).
Several serine proteases modulate endogenous ENaC cur-
rents and ENaC/Deg subunits in in vitro expression systems (9).
The large extracellular loops ofASICs andENaCs containmany
arginines and lysines that form putative sites for cleavage by
serine proteases. For example, proteolytic cleavage of ENaC
and ENaC subunits by furin convertases occurs in the trans-
Golgi apparatus during ENaCmaturation. These channels may
be clipped further by secreted serine proteases (e.g. trypsin)
or membrane-bound proteases (e.g. prostasin). Noncleaved
ENaC channels also traffic to the plasmamembrane, where
they provide a pool of “near silent” channels, ready to be cleaved
into active ones (9–13). The exact mechanism of how cleavage
activates ENaC is incompletely understood, but one hypothesis
is that cleavage removes inhibitory peptides from ENaC and
ENaC (12). An alternative mechanism of ENaC activation by
cleavage, proposed by Hu et al. (14), involves loss of the ENaC
N terminus (including the first transmembrane domain) from
the channel complex. Cleavage by proteases does not change
the number of ENaC channels at the surface but rather
increases channel open probability and is a mechanism for reg-
ulating ENaC activity (13). The sites for cleavage of ENaCs by
many proteases such as prostasin, furin, and trypsin have been
identified and are located in the N-terminal part of the extra-
cellular loop (12).
ASIC1 homomers or ASIC1-containing heteromeric
ASICs can also be modified by serine proteases such as tryp-
sin, chymotrypsin, and proteinase K. Protease treatment
disrupts the Psalmopoeus cambridgei venom block of heter-
ologously expressed ASIC1 channels, decreases the peak
acid-activated current, and shifts the pH50 of activation to a
more acidic pH (15, 16). Because ASICs inactivate quickly
upon exposure to a low pH, this shift could be important in
extracellular acidosis, where a sustained decrease in extra-
cellular pH could inactivate ASICs. The only known site of
ASIC cleavage by proteases that has been identified is the
trypsin cleavage site at Arg-145 (16).
Recently, the serine protease matriptase (also known as
channel-activating protease 3 (CAP3)) has been identified as a
modulator of ENaC activity in vitro. When matriptase is co-
expressed withENaC subunits inXenopus laevis oocytes, it
causes a 10-fold increase in INa (17, 18). However, this func-
tional effect of matriptase on ENaC has not been correlated
with the presence of ENaC proteolytic cleavage fragments.
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Matriptase is an 80–90-kDa type II transmembrane pro-
tease that belongs to the S1 family of trypsin-like serine pro-
teases. It contains an extracellular C-terminal catalytic
domain and an intracellular N terminus. It was first de-
scribed as a gelatinolytic activity in cultured breast cancer
cells and was isolated in a complex with its cognate inhibitor,
hepatocyte growth factor activator inhibitor-1 (HAI-1) from
human milk (19). Matriptase is synthesized as an inactive, sin-
gle-chain zymogen. Its activation is complex; it is first cleaved in
the secretory pathway by an unknown protease at Gly-149, and
later at Arg-614 in the serine protease domain, after it reaches
the surface. This last cleavage converts matriptase into the
active protease.Mutations in any of the catalytic triad (His-656,
Asp-711, and Ser-805) amino acids render matriptase inactive
by making it unable to undergo the activation site cleavage at
Arg-614 (20, 21).
Matriptase is an epithelial protease and has important phys-
iological functions. It is crucial for epidermal barrier formation
and is involved in hair follicle growth and thymocyte develop-
ment. In addition, matriptase has been implicated in many epi-
thelial cancers. It is consistently expressed in human epithelial
tumors of the head, neck, mesothelium, breast, ovary, cervix,
prostate, lungs, and gastrointestinal tract, and its overexpres-
sion in keratinocytes results in spontaneous squamous cell
carcinomas. In most tumors matriptase RNA and protein are
up-regulated, and there is a positive correlation between
matriptase expression and tumor grade (20, 22). Interestingly,
matriptase inhibition in vitro or in xenografted tumors with
siRNAs or antisense oligodeoxyribonucleotides decreases inva-
sion (20, 22, 23). Additionally, overexpression of the serine pro-
tease inhibitor HAI-1 suppresses the in vitro invasion of glio-
blastoma cells (24).However, the target ofHAI-1 in these assays
is not known, because HAI-1 inhibits several other serine pro-
teases in addition to matriptase.
The goal of this study was to test the hypothesis that
matriptase can modulate the activity of ASIC1 channels
through proteolytic cleavage. Matriptase cleaved ASIC1 when
the two were co-expressed in X. laevis oocytes or CHO cells.
Matriptase decreased ASIC1 function but had no effect on the
function of ASIC2. The effects of matriptase on the function
and proteolytic cleavage of ASIC1 could be prevented by
mutagenesis of threematriptase recognition sites on the ASIC1
extracellular loop.
EXPERIMENTAL PROCEDURES
RNA Extraction and Reverse Transcription-PCR—Total
RNAs were isolated from freshly excised human tissues
(obtained from Birmingham Neurosurgery Brain Tissue Bank
under Institutional Review Board approval) using TRIzol
(Invitrogen) and following the manufacturer’s instructions as
described previously (5). Total RNAs fromhumanprimary cells
or human cell lines were isolated with the RNeasy RNA extrac-
tion kit (Qiagen) as specified by themanufacturer. The integrity
and quality of the isolated RNAs were checked with denaturing
agarose-formaldehyde gel electrophoresis. The RT-PCR reac-
tion was done using a One-Step RT-PCR kit (Qiagen) with 500
ng of RNA and each primer at 0.6 M. The matriptase forward
and reverse primer sequences were 5-CACAAGGAGTCG-
GCTGTGAC-3 (forward) and 5-GAGGGTAGGTGCCACA-
CAA-3 (reverse). Standard RT-PCR conditions were used: at
50 °C, 1 cycle for 30 min; at 95 °C, 1 cycle for 15 min; at 94 °C
1 min, 54 °C 1 min, and 72 °C 1 min, for 35 cycles; at 72 °C,
1 cycle for 10min. The RT-PCR product was visualized by elec-
trophoresis in a 2% agarose gel. A negative control with noRNA
in the RT-PCR reaction was included with each experiment to
guard against contamination.
Cell Culture and Transfections—Primary non-tumor human
astrocytes isolated from astrogliosis regions and primary
humanGBMswere obtained from theUniversity of Alabama at
Birmingham Neurosurgery Brain Tissue Bank (Institutional
Review Board Approval X050415007). The cell lines used
(U87MG, D54MG, SKMG, U251MG, and CHO K1) have been
described previously (7, 8, 25). All cells were cultured in Dul-
becco’s modified Eagle’s medium/F-12 (1:1) (Hyclone) with
10% fetal bovine serum (Hyclone) andweremaintained in a 95%
O2, 5% CO2 humidified incubator at 37 °C.
For transfections, CHO K1 cells were split into 6-well tissue
culture dishes and transiently transfected with 2 g of each
plasmid DNA and 10 l of Lipofectamine 2000 reagent
(Invitrogen) per well following the manufacturer’s protocol.
Whole-cell lysates were obtained at 48 h post-transfection as
described below.
Plasmids, Tagged Constructs, and Site-directed Mutagenesis—
The plasmids used contained the DNA sequence of human
ASIC1b (NM_001095), human ASIC2b (NM_001094), and
human matriptase (NM_021978). N- or C-terminal fusions of
eGFP on hASIC1b and hASIC2b were prepared as described
previously (26). The channel sequences were modified with
PCR by the addition of 5-XhoI and 3-BamHI restriction sites
using Pfu polymerase (Stratagene). The constructs were then
subcloned into the pEGFP-N1 or pEGFP-C1 vectors (Clon-
tech). The DNA sequences coding for the eGFP fusion channel
proteins were subcloned, using NheI and AflII for the C-termi-
nal tags and NheI and BamHI for the N-terminal tag, into the
pcDNA 3.1 vectors (Invitrogen). The ASIC1-hemagglutinin
(HA) construct with HA in the extracellular loop between Phe-
147 and Lys-148 and the ASIC2-eYFP construct have been
described previously (25, 26). For the ASIC2-HA construct, a
newBstBI sitewas added in the extracellular loop ofASIC2with
PCR, and an HA tag was inserted into the BsTB1 site at
Thr-239.
Site-directed mutagenesis to introduce point mutations in
thematriptase sites on ASIC1 was carried out as described pre-
viously using the QuikChange II XL mutagenesis kit (Strat-
agene), sense and antisense primers, and ASIC1-EGFP-N1 in
pcDNA3.1 as template DNA (25). The primers contained the
necessary base changes tomutate the desired arginines (Arg) or
lysines (Lys) to alanines (Ala).
The catalytically inactive S805A-matriptase-pcDNA3.1
was generated using the QuikChange II XL site-directed
mutagenesis kit (Stratagene) and primers containing the appro-
priate base pairs (18). All of the generated mutations were con-
firmed byDNA sequencing (HeflinGenetics Center, University
of Alabama at Birmingham).
Expression in Xenopus Oocytes—Oocytes were isolated sur-
gically from anesthetized female X. laevis frogs and were colla-
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genase-treated, sorted, and maintained as described previously
(25). These procedures were in accordance with and approved
by the Institutional Animal Care and Use Committee of the
University of Alabama at Birmingham. cRNA preparations and
injections into oocytes have also been described previously (25).
cRNAs were transcribed using the high yield in vitro transcrip-
tion kit and CAP analog (Ambion). Each oocyte was injected
with 12 ng of channel cRNA in 50 nl of H2O with matriptase or
with S805A-matriptase cRNAs as indicated in the experiments.
Electrophysiological Analysis—Two-electrode voltage clamp
at a holding potential of 60 mV was performed at room tem-
perature 1–4 days post-injection as described previously (25).
Oocytes were placed in a recording chamber (500 l) and
impaled with two glassmicroelectrodes filled with 3 MKCl with
resistances of 0.5 to 2 megohms. Whole-cell currents were
recorded with a Geneclamp 500B amplifier with a steady-state
restore switchmodification (Axon Instruments). A SF-77BPer-
fusion Fast-Step (Warner Instruments) was used to rapidly
exchange the solution bathing the oocyte from ND96, pH 7.4
(96 mM NaCl, 1 mM MgCl2, 2 mM CaCl2, 2 mM KCl, and 5 mM
HEPES), toND96, pH4.0 (same asND96, pH7.4, butwith 5mM
MES instead of HEPES). The oocyte was exposed to pH 7.4 for
13 s, to pH 4.0 for 13 s to maximally activate the channels, and
again to pH 7.4 for 13 s to allow for recovery of the acid-acti-
vated channels. To obtain the pH activation curves, oocytes
were exposed to sequentially lower activation pHs (pH 7.0, 6.5,
6.0, 5.5, 5.0, and 4.0). The peak current at each activation pH
was normalized to the peak pH 4.0 current within each oocyte.
The normalized values were fit to the Hill equation, I  Imax/
[1(10pH50/10pH)nH], where Imax is the maximal current
(current at pH 4.0), pH50 is the pH at which half the maximal
current is obtained, and nH is the Hill coefficient. pH50 values
and Hill coefficients were obtained separately for each oocyte
by means of a “brute force” algorithm. Predicted values for the
normalized currents across the range of experimental pH val-
ues were obtained by means of the Hill equation, and the sum-
squared error between predicted and observed currents for
each combinationwas computed. TheHill coefficient and pH50
combination that minimized the sum-squared error was then
selected.
Reagents—The recombinant human matriptase/ST14 cata-
lytic domain was obtained from R&D Systems, Inc. and con-
tained anN-terminal sequence corresponding to the beginning
of the catalytic domain with Val-615. Purified and folded psal-
motoxin (PcTX-1) peptide was obtained from Peptides Inter-
national in the trifluoroacetate form and with formed disulfide
bonds. The cell-permeable proteasome inhibitor MG132 was
from Calbiochem.
Whole-cell Lysates and Immunoblot Analysis—Mammalian
cell lines growing on tissue culture dishes were washed twice
with ice-cold phosphate-buffered saline (PBS) and incubated
in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5,
1% Triton-X-100, and Complete protease inhibitor mixture
(Roche Applied Science)) at 4 °C for at least 30 min. The cells
were scraped off the dishes; the lysate was transferred to a
microcentrifuge tube and passed through a 21-gauge needle
5–7 times. After centrifugation at 12,000 rpm for 20min at 4 °C,
the supernatants were saved, and 30–50 g of lysate was used
for Western blot. All experiments were repeated at least three
times.
Oocyte whole-cell lysates were obtained by lysing oocytes
at 2–3 days post-injection in 20 l of Triton homogenization
buffer/oocyte as described previously (25). After protein assay,
equal amounts of protein (50 g) were used for Western blot.
All experiments were repeated at least three times.
The lysates were boiled at 95 °C for 7 min in 1 Laemmli
sample buffer (62.5mMTris HCl, pH 6.8, 25% glycerol, 2% SDS,
10% -mercaptoethanol, and 0.01% bromophenol blue) and
subjected to 8% (for matriptase blots only) or 12% SDS-PAGE
with 4% stacking gels. The separated proteins were transferred
to Immobilon-P transfer polyvinylidene difluoride (PVDF)
membranes (Millipore). Membranes were blocked with 10%
nonfat dry milk in Tris-buffered saline with Tween (TBS-T)
(100mMTris, pH 7.5, 150mMNaCl, and 0.1%Tween-20) for 30
min to 1 h at room temperature or overnight at 4 °C and probed
with the appropriate antibodies in 3%milk in TBS-T overnight
at 4 °C or 2 h at room temperature. The following antibodies
were used: mouse anti-matriptase/ST14 monoclonal antibody
(R&D Systems) at 1:500, mouse anti-GFP monoclonal anti-
body (Abgent) at 1:2000, and rat anti-HA antibody (Roche
Applied Science) at 1:2000. The blots were washed with TBS-T
and incubated in goat anti-mouse horseradish peroxidase
(HRP)-conjugated antibody (Jackson ImmunoResearch Labo-
ratories, 1:10,000) or goat anti-rat HRP-conjugated antibody
(Thermo Scientific, 1:10,000), as appropriate, in 5% milk in
TBS-T. The blots were developed in SuperSignal West Pico
Substrate (Thermo Scientific) and exposed to x-ray film
(Denville).
Data Analysis and Statistics—Data analysis was done with
Clampfit 9 (Molecular Devices) or Excel. Data are presented as
means  S.D. or means  S.E. as noted. Statistical significance
was set at p  0.05, and statistical tests were done with Excel or
GraphPad Prism 5. Two-tailed t tests (unpaired or paired) or
comparisons of multiple groups with post hoc tests were cho-
sen as appropriate to determine the p values.
RESULTS
Detection of Matriptase RNA and Protein in Glioma Cells—
Matriptase expression has been reported in numerous epi-
thelial tissues, both normal and cancerous (20). However, in
studies in which matriptase localization was determined
by Northern blot analysis of rodent tissues, matriptase
RNA was not detected in the normal brain (17, 27). ENaC/
Deg subunits are candidate substrates for matriptase,
because matriptase increases the amiloride-sensitive current
of ENaC when the two are co-expressed in Xenopus
oocytes (18). Because we have previously shown that glioma
cells express ENaC/Deg subunits and because matriptase is
involved in malignant progression, we looked for matriptase
expression in high grade glioma cells. RT-PCR results showed
that matriptase mRNA was expressed in two glioma cell lines
(U251 and SKMG), in three different freshly excisedGBMs, and
in two different freshly resected grade III anaplastic astrocyto-
mas (AA); matriptase RNA was not detected either in primary
human astrocytes (from astrogliosis regions) or in astrogliosis tis-
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sue (Fig. 1A). Matriptase protein expression in glioma was con-
firmed by Western blot of glioma cell lines and human pri-
mary GBM lysates. Matriptase was detected at 75 kDa.
Even though we could not detect matriptase mRNA in the
primary human normal astrocytes, we could detect
matriptase protein there (Fig. 1B); therefore, we cannot rule
out that very low levels of matriptase mRNA, undetected by
standard RT-PCR, are expressed in normal astrocytes.West-
ern blot data showed that matriptase protein expression was
lower in normal astrocytes compared with the primary
human GBMs or glioma cell lines (Fig. 1B).
Matriptase Inhibits the Function of ASIC1 and Has No
Effect on the Function of ASIC2 in Xenopus Oocytes—To test
the hypothesis that matriptase regulates ASIC1, we assessed
ASIC1 function by measuring the whole-cell peak pH 4.0-
activated current of oocytes expressing ASIC1  matriptase.
Unlike its effect on ENaC, matriptase decreased the peak
pH 4.0 current of ASIC1. A similar effect of proteases on
ASIC1 has been reported for trypsin (15). A catalytically
inactive matriptase, with a mutation in one of the catalytic
triad amino acids (Ser-805 to Ala),
did not have an effect on the max-
imum ASIC1 current (Fig. 2A).
The dose-response of effect of
matriptase was obtained by mea-
suring ASIC1 whole-cell currents at
pH 4.0 in oocytes injected with 12
ng of ASIC1 cRNA and increasing
amounts of matriptase cRNA (0–12
ng) as indicated in Fig. 2B. The
injection of 2 ng of matriptase with
ASIC1 did not have a statistically
significant effect on the peak pH 4.0
current. However, ASIC1 current
decreased significantly when 4 ng or
higher amounts ofmatriptase cRNA
were used. The inactive S805A
matriptase did not have a statisti-
cally significant effect on ASIC1
even at the highest concentration
used (Fig. 2B).
To determine whether the effect
ofmatriptase onASIC1was specific,
we injected oocytes with another hu-
man ASIC family member, ASIC2.
Matriptase had no effect on the
whole-cell peak current of ASIC2,
suggesting some specificity of its
action on ASIC1 (Fig. 2C).
When the purified recombinant
matriptase catalytic domain was
added to the recording bath (50
ng/ml for 5 min, the same time
scale and concentration used in its
activity assay by the manufac-
turer), the current of ASIC1 de-
creased, whereas that of ASIC2 did
not change significantly (Fig. 2D).
We used the purified matriptase catalytic domain because of
the shorter time scale compared with co-injection with ASIC1
followed by a two-day expression. However, it was not possible
to compare the amount of matriptase present in the bath and
available to cleave the ASIC1 channels with the amount of
matriptase protein that the oocyte could express in 2 days after
injection. The addition of recombinant active matriptase to the
bath reduced the ASIC1 current by 20%; this decrease was
smaller than that observed when matriptase was co-injected in
oocytes with ASIC1, but it was statistically significant. It has
been shown previously that 2 g/ml (about 1 M) trypsin for 5
min decreases the peak pH 4.0 current of ASIC1 by only 10%,
whereas 20 g/ml trypsin decreases it by 30–40% (15). These
trypsin concentrations are much higher than the 50 ng/ml
(about 2 nM) used in our experiments formatriptase. Because of
the limited amount of purified matriptase catalytic subunit, we
were unable to use higher concentrations ofmatriptase in these
experiments. The physical closeness of expressed matriptase
versus thematriptase added to theASIC1 channels, and the fact
that matriptase could bemore active in its native conformation
FIGURE 1. RT-PCR and Western blot detection of matriptase in glioma cell lines and fresh GBM tissues.
A, agarose gels of RT-PCR products detect matriptase RNA in SKMG and U251MG cell lines, freshly resected
GBM, and anaplastic astrocytoma (AA). A matriptase message is not detected in primary human astrocytes or
fresh astrogliosis tissue. No RNA in the RT-PCR reaction is used as a negative control. B, Western blot of whole-
cell lysates with a matriptase antibody shows that expression of matriptase in glioma cell lines (D54MG,
U251MG, and U87MG) and two different human primary GBM is higher than its expression in two different
primary human astrocytes. The blot was probed for actin as a loading control.
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compared with the purified protein, could also have contrib-
uted to the result obtained with the catalytically active purified
matriptase. Although the purified matriptase decreased ASIC1
peak pH 4.0 current, it had no statistically significant effect on
the peak current of ASIC2-injected oocytes (Fig. 2D).
Matriptase Does Not Change the pH Activation Curve or
PcTX-1 Block of ASIC1—Matriptase decreased the peak cur-
rent of ASIC1, and for this decrease to occur, matriptase clearly
required a functional catalytic domain (S805A has no effect on
ASIC1), suggesting that matriptase cleaved the ASIC1 chan-
nels. Trypsin also cleavesASIC1, and it affects the pHactivation
and channel inhibition by the venom of P. cambridgei (16).
Trypsin shifts the pHactivation curve ofASIC1 to amore acidic
pH and disrupts the venom block of ASIC1 (16). Therefore, we
hypothesized thatmatriptase would also affect these character-
istics of the ASIC1 current. We obtained a pH activation curve
and PcTX-1 sensitivity of ASIC1  matriptase oocytes. For
the pH activation curve, oocytes injected with ASIC1,
ASIC1  matriptase, or ASIC1  matriptase S805A were sub-
jected to two-electrode voltage clamp and first exposed to
pH 7.4 followed by sequentially lower pH levels ranging
from pH 7.0 to 4.0, returning to pH 7.4 after each activation.
The peak current at each activation pH was normalized to
the pH 4.0 current for each oocyte. The normalized values
were then plotted against the activation pH to obtain the pH
activation curves and were fitted to the Hill equation to
obtain pH50 values and Hill coefficients. As shown in Fig. 3A,
there is no difference in the pH activation curves in ASIC1,
ASIC1  matriptase, or ASIC1  matriptase S805A. The pH50
values and Hill coefficients were also not statistically different
FIGURE 2. Matriptase decreases the peak acid-activated current of ASIC1 but not that of ASIC2 in Xenopus oocytes. A, peak IpH4.0 were measured by
two-electrode voltage clamp in oocytes injected with 12 ng of ASIC1 cRNA alone, ASIC1 with matriptase (8 or 12 ng), or ASIC1 with the catalytically inactive
matriptase S805A (8 ng). Representative traces are shown above each graph. Graph values are means  S.D. The numbers of oocytes measured are from two to
three experiments and are shown in parentheses. The nonparametric Kruskal-Wallis test with Dunn’s post hoc test was used to determine the p value.
B, dose-response of effect of matriptase on the peak IpH4.0 of ASIC1. Oocytes were injected with 12 ng of ASIC1 and increasing amounts of matriptase cRNA.
Values are means  S.D. The numbers of oocytes measured are shown in parentheses and are from five experiments. The nonparametric Kruskal-Wallis test with
Dunn’s post hoc test was used to determine the p values. C, normalized IpH4.0 of oocytes injected with 12 ng of ASIC2 cRNA alone or ASIC2 with 12 ng of
matriptase. Unlike the effect on ASIC1, matriptase does not have an effect on the peak IpH4.0 of ASIC2. Representative traces are shown. Values are means  S.D.,
and the numbers of oocytes measured are shown in parentheses. The p value was determined with a two-tailed, unpaired t test. D, oocytes were injected with
ASIC1 or ASIC2 cRNA. After the peak IpH4.0 current was measured, catalytically active purified matriptase was added to the bath for 5 min at 50 ng/ml, and the
peak IpH4.0 was measured again. The graph shows normalized values: for each oocyte, the peak IpH4.0 measured “before” and “after” matriptase addition was
normalized to the “before” IpH4.0. The peak IpH4.0 of ASIC2 did not decrease after the addition of active matriptase to the bath. Representative traces for ASIC1
and ASIC2 before and after matriptase are shown. The p values were obtained with a two-tailed paired Student’s t test of the raw current values before and after
matriptase. Values are means  S.D. The numbers of oocytes measured are shown in parentheses.
FIGURE 3. Matriptase does not change the pH activation curve or inhibition by PcTX-1 of ASIC1. A, pH activation curve of currents measured in oocytes
injected with 12 ng of ASIC1 alone, ASIC1 plus 8 or 12 ng of matriptase, or ASIC1 plus 12 ng of matriptase S805A. Oocytes were exposed to decreasing activation
pH levels from 7 to 4.0. The peak current at each activation pH was normalized to the peak IpH4.0 for each oocyte. Representative pH activation curves and the
pH protocol used are shown. The graphed values are means  S.D. of 10 oocytes (ASIC1), 10 oocytes (ASIC1  matriptase), and 7 oocytes (ASIC1  matriptase
S805A) from two or three different batches. B, peak IpH4.0 was measured in oocytes expressing ASIC1 alone or ASIC1 with 12 ng of matriptase. 100 nM PcTX-1 in
the pH 7.4 solution abolished the IpH4.0 of control ASIC1-injected oocytes as well as of those co-injected with matriptase. Traces shown are representative of
three oocytes for ASIC1 and three oocytes for ASIC1 and matriptase.
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(pH50  6.18 (S.D.  0.18), nH  1.77 (S.D.  0.32), n  10 for
ASIC1; pH50  6.20 (S.D.  0.08), nH  1.64 (S.D.  0.41), n 
10 for ASIC1  matriptase; pH50  6.22 (S.D.  0.13), nH 
1.71 (S.D.  0.49), n  7 for ASIC1  S805A).
For the PcTX-1 block experiments, PcTX-1 was included in
the pH 7.4 solution at 100 nM. PcTX-1 inhibited not only the
ASIC1 current but also the current ofASIC1  matriptase (Fig.
3B). This is different from trypsin, which removes the venom
block of ASIC1 (15). Because the characteristics of the cur-
rent (pH activation and PcTX-1 block) measured in
ASIC1  matriptase were not different from those of ASIC1
(but matriptase almost abolished the whole-cell peak cur-
rent, and its catalytic site was required for this effect), it is
likely that the current measured in
ASIC1  matriptase oocytes is
from a population of noncleaved
ASIC1 channels and that the
cleaved channels are nonfunc-
tional. The other possibility is that
the cleaved channels have the same
properties as the noncleavedASIC1.
However, the experiments below
detecting the presence of ASIC1
cleavage products and determining
the location of the possible sites
where matriptase cleaves ASIC1 sup-
port the hypothesis that the current
measured in ASIC1matriptase is
due to a population of noncleaved
channels.
Matriptase-specific Fragments for
ASIC1 but Not ASIC2 Are Observed
in Xenopus Oocytes and in Trans-
fectedCHOK1Cells—Todetermine
whether ASIC1 channels are cleaved
bymatriptase,weobtainedwhole-cell
lysates from oocytes expressing N-
and C-terminal eGFP-tagged ASIC1
and matriptase. First, we measured
whole-cell peak currents at pH 4.0
by two-electrode voltage clamp
of ASIC1-GFP (C-terminal eGFP
tag)  matriptase and GFP-ASIC1
(N-terminal eGFP tag)  matriptase
to ensure that the tag did not affect
the results. Matriptase decreased
the current of ASIC1-GFP and that
of GFP-ASIC1 similarly to the non-
tagged ASIC1 (Fig. 4, A and C). Fol-
lowing oocyte lysis and immuno-
blotting with a GFP antibody, in
ASIC1-GFP  matriptase andGFP-
ASIC1  matriptase oocytes we
observed several cleavage products
thatwere not detected in the control
lanes (Fig. 4, B and D). The full-
length GFP-tagged ASIC1 was
detected at 100 kDa, because the
GFP tag adds 25 kDa to the 75-kDa ASIC1 protein (see Fig. 4
schematics). For the ASIC1-GFP constructs, five fragments
were detected due to matriptase, and they are indicated by
arrows in Fig. 4B.
The schematic below Fig. 4, A and B show the approximate
positions of the possible cleavage sites that would result in the
observed fragments. It also shows the approximate sizes of the
fragments. Fragments that are not attached to GFP would not
be detectablewith theGFP antibody. The two largest fragments
at 70–75 kDa could result from cleavage in the N-terminal part
of the extracellular loop. The two fragments between 37 and 50
kDa could result from cleavage at a site near the C terminus of
the extracellular loop, and the smallest fragment could be from
FIGURE 4. Detection of matriptase-specific cleavage fragments of GFP-tagged ASIC1 but not of tagged
ASIC2 in Xenopus oocytes. A and C, normalized IpH4.0 of oocytes injected with C-terminal GFP-tagged ASIC1
(A) or with N-terminal GFP-tagged ASIC1 (C) with or without 12 ng of matriptase cRNA shows that matriptase
significantly decreases the current of ASIC1-GFP (A) and GFP-ASIC1 (C). The values are means  S.D. The
numbers of oocytes measured are shown in parentheses; p values were determined with unpaired two-tailed t
tests. B and D, Western blot of oocyte lysates with GFP antibody, which detects ASIC1 fragments in the
matriptase lane for both the ASIC1-GFP (B) and GFP-ASIC1 (D) samples. The arrows point to GFP-tagged ASIC1
cleavage products. The schematics of ASIC1-GFP (below A and B) and GFP-ASIC1 (below C and D) show the
locations of possible cleavage sites in each construct and the fragment sizes. The black boxes represent the two
transmembrane domains. E, Western blot of oocyte whole-cell lysates from oocytes injected with ASIC2-YFP
with or without 12 ng of matriptase cRNA or 12 ng of matriptase S805A cRNA. The GFP antibody does not
detect any fragments for ASIC2 in the ASIC2-YFP plus matriptase samples, suggesting that matriptase does not
cleave ASIC2.
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cleavage at a site very near the second transmembrane domain.
Alternatively, the smaller cleavage products could be due to
further cleavage of the largest fragments by other endogenous
oocyte serine proteases.
A schematic of GFP-ASIC1 is shown below Fig. 4,C andD. It
illustrates the same possible cleavage sites as determined from
the ASIC1-GFP construct, and the corresponding approximate
fragment sizes that would be expected from cleavage at those
sites. Two fragments at 35–40 kDa are detected for GFP-
ASIC1. Their sizes correspondwell to the twoN-terminal sites,
which would result in the two 70–75-kDa fragments for
ASIC1-GFP (Fig. 4B). The schematic shows that larger frag-
ments at 80–90 kDa are also expected for GFP-ASIC1, but no
such fragments are detected in the blot in Fig. 4D. It is possible
that the N-terminal 80–90 kDa fragments are cut further into
smaller pieces by endogenous serine proteases.
Matriptase had no effect upon the function of ASIC2. A
Western blot of lysates from oocytes expressing a GFP- or YFP-
tagged ASIC2 and matriptase shows that there are no
matriptase cleavage products of ASIC2-YFP and that the full-
length ASIC2-YFP protein did not decrease as did the full-
length ASIC1-GFP or GFP-ASIC1 (Fig. 4E). These results sup-
port the hypothesis that the functional effect of matriptase on
the current of ASIC1 is accompanied by a decrease in full-
length channels and the presence of cleavage products, whereas
the lack of effect on ASIC2 is accompanied by a lack of ASIC2
cleavage products or substantial decrease in the full-length
protein.
We also tested the effect of matriptase on an ASIC1 con-
struct with an HA tag in the extracellular loop. The data with
the eGFP-tagged ASIC1 and ASIC2 showed that matriptase
cleaves ASIC1 but not ASIC2. ASIC1-HA and ASIC2-HA were
used to further confirm these findings. Because the HA tag (at
Phe-147 on ASIC1 and Thr-139 on ASIC2) is in a different
position than the N or C terminus of the protein, we would
detect different ASIC fragments than when using GFP-tagged
ASICs. The ASIC1-HA and ASIC2-HA constructs did not
differ from the untagged ASIC1 and ASIC2 in the way that they
were functionally affected by matriptase. The current of
ASIC1-HA  matriptase was decreased compared with con-
trol; matriptase had no effect on ASIC2-HA (Fig. 5, A and C).
Western blots with an HA antibody detected full-length
ASIC1-HA or ASIC2-HA at the expected size of about 75 kDa,
and only ASIC1-HA was cleaved by matriptase.
A schematic of theASIC1-HA construct showing the relative
position of the HA tag, the positions of the same possible cut
sites that were deduced from Fig. 4B, and the approximate sizes
of the fragments is shown below Fig. 5, A and B. Only the frag-
ments that would contain theHA tag andwould thus be detect-
able by an HA antibody were considered. The sizes (in kDa) at
the top of the schematic are for fragments from the N terminus
ofASIC1 to the indicated cleavage site. The size indicated below
the schematic is for the fragment from theC terminus of ASIC1
to the first potential N-terminal cleavage site. This is 50 kDa,
corresponding well to what is observed in the blot in Fig. 5B. As
the schematic shows, there are a few fragments with sizes of
45–50 kDa; we could not tell the exact cleavage site that
resulted in the 50-kDa fragment observed. It is possible that this
fragment is from cleavage at the first N-terminal site and rep-
resents the C-terminal linked fragment, and the larger N-ter-
minal linked fragments get cleaved further by proteases (espe-
cially as the largest N-terminal fragments for GFP-ASIC1 were
not seen). The catalytically inactive matriptase S805A did not
cleave ASIC1-HA, consistent with its lack of effect on the func-
tion of ASIC1. A few nonspecific smaller fragments were
observed for ASIC1-HA and ASIC2-HA without matriptase
(Fig. 5, B and D). These fragments could be degradation prod-
ucts andwere not observed in noninjected oocytes (not shown).
In agreement with theASIC2 functional andWestern blot data,
no ASIC2-HA cleavage products specific to matriptase were
detected, further supporting the hypothesis that matriptase
does not cleave ASIC2.
FIGURE 5. Detection of cleavage fragments of HA-tagged ASIC1 but not
HA-tagged ASIC2 in Xenopus oocytes. A and C, normalized IpH4.0 of oocytes
injected either with ASIC1-HA (A) or ASIC2-HA (C) with or without 8 or 12 ng of
matriptase cRNA. Matriptase decreases the peak IpH4.0 of ASIC1-HA but not
that of ASIC2-HA. Data are means  S.D. The numbers of oocytes measured
are shown in parentheses. The p values were determined with unpaired two-
tailed t tests. B and D, consistent with the effect of matriptase on the function
of the channels, Western blotting of whole oocyte lysates with an HA anti-
body detects fragments of ASIC1-HA (B) but not ASIC2-HA (D), suggesting
that matriptase does not cleave ASIC2. The schematic of ASIC1-HA (below A
and B) shows the locations of possible cleavage sites in the construct and the
predicted fragment sizes. The black boxes represent the two transmembrane
domains.
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In the above experiments ASIC1 and matriptase were heter-
ologously co-expressed in Xenopus oocytes. Because there may
be differences between heterologous expression systems, we
used mammalian CHO K1 cells to test the hypothesis that
matriptase cleaves ASIC1 specifically, whereas it does not
cleave ASIC2. In these experiments, ASIC1-GFP full-length
protein was detected at 100 kDa in transfected CHO cells, and
its intensity decreased with increasing amounts of matriptase
DNA (Fig. 6A). The relative densitometry values for each band
were normalized to the control ASIC1-GFP with nomatriptase
(Fig. 6A, first lane on the blot). The GFP antibody detected
somenonspecific fragments thatwere present in all the samples
transfected with ASIC1-GFP but were not present in nontrans-
fected CHO cells. There were two faint fragments between 37
and 50 kDa specific to catalytically activematriptase. These two
fragments were present only in the matriptase lanes and not in
the control lane or the catalytically inactive matriptase S805A
lane.
Because these fragments were difficult to detect, we hypoth-
esized that after cleavage, they were being sent for degradation.
We tested this hypothesis by treating the transfected CHOcells
with the proteasome inhibitorMG132 (5 g/ml for 5 h or over-
night) at 48 h post-transfection with 2 g of ASIC1-GFP alone,
2 g of ASIC1-GFP  2 g of matriptase, or 2 g of ASIC1-
GFP2gmatriptase S805A.As shown inFig. 6B, in the samples
treated withMG132, the two proteolytic fragments between 37
and 50 kDa could be clearly detected in thematriptase lane. Fig.
6B shows the normalized densitometry of the full-length bands
and the two detected fragments. The nonspecific bands present
in all of the lanes were ignored because they were not specific to
matriptase. All of the bandswere normalized to the signal of the
full-length untreated ASIC1-GFP. The graph shows that the
intensity of the full-length ASIC1-GFP protein decreases with
matriptase, and two fragments, labeled F1 (fragment 1) and F2
(fragment 2), appear in the matriptase lanes (Fig. 6B). The
intensities of all the bands, including the two fragments,
increased when the cells were pretreated with the proteasome
inhibitor. The inactive matriptase S805A did not decrease the
signal of the full-length ASIC1-GFP.
The same experiment as shown in Fig. 6B was repeated for
the N-terminal GFP-tagged ASIC1 (GFP-ASIC1). One frag-
ment was observed for GFP-ASIC1 in thematriptase lanes (Fig.
6C). The nonspecific bands that were present in all of the lanes
for the ASIC1-GFP construct were not detected with the GFP-
ASIC1.MG132 pretreatment increased the intensities of all the
bands, including the fragment (Fig. 6C densitometry). No frag-
ments were observed either in the control or the matriptase
S805A in the untreated and MG132-treated samples.
The effect of matriptase on a C-terminal GFP-tagged ASIC2
(ASIC2-GFP) in CHO cells was tested to determine if the effect
of matriptase on ASIC1 was specific. Surprisingly, a substan-
tial decrease in the full-length ASIC2-GFP was observed
with matriptase, but no ASIC2-GFP cleavage fragments spe-
cific to matriptase could be detected even when cells were
treated with MG132 (Fig. 6D). In the presence of MG132, a
fragment appeared at 37 kDa. This fragment was present in
all of the ASIC2-GFP lanes with MG132, including the con-
trol with ASIC2-GFP alone and the ASIC2-GFP with the inac-
tive matriptase S805A. Because this fragment was not specific
to matriptase (and its intensity actually decreased with
matriptase comparedwith control or inactivematriptase) itwas
ignored andwas not included in the densitometry. The absence
of ASIC2-GFP fragments with matriptase suggests that
matriptase does not cleave ASIC2. However, because we did
detect a decrease in ASIC2-GFP protein with matriptase (in
both untreated andMG132-treated as compared with the con-
trol/inactive matriptase) we cannot exclude the possibility that
in CHO cells, matriptase could cleave ASIC2 and we were
unable to observe ASIC2 fragments. Another possibility is that
the decrease in ASIC2-GFP expression with matriptase is an
indirect effect of matriptase on protein expression rather than
cleavage ofASIC2bymatriptase. In all of these experiments, the
catalytically inactive S805A matriptase was able to prevent the
effect of matriptase on ASIC1 or ASIC2 (Fig. 6).
It is important to note some differences between expression
in oocytes andmammalianCHOcells: several ASIC1 fragments
were observed with the ASIC1-GFP construct in oocytes com-
pared with only two fragments in CHO cells; two fragments
were observed with the GFP-ASIC1 construct in oocytes com-
pared with one fragment in CHO cells. Matriptase did not
result in ASIC2 fragments either in oocytes or in CHO cells,
and it did not dramatically decrease ASIC2 expression in
oocytes; however, matriptase decreased ASIC2 expression in
CHO cells. Despite these differences in the two expression sys-
tems, matriptase-specific fragments were detected for ASIC1,
but not forASIC2, in both oocytes andCHOcells. However, the
sites of cleavage or downstream signaling events caused by
matriptase may be different in the two expression systems.
Identification of Matriptase Cleavage Sites on ASIC1—Be-
cause matriptase decreased the ASIC1 current and cleaved
ASIC1 but had no effect on the function of ASIC2, we searched
for matriptase cleavage sites on the ASIC1 and ASIC2 amino
acid sequences. The preferred cleavage sequence of matriptase
and the activation sites of known matriptase substrates were
obtained from Uhland (20). The four preferred residues proxi-
mal to the cleavage site (P4, P3, P2, and P1) and also P1, which
is the position distal to the cleavage site, were entered in the
FindPatterns program of Genetics Computer Group software.
Arginine, lysine, and non-basic amino acids were entered for
both P4 and P3; serine, alanine, phenylalanine, leucine, glycine,
and arginine were entered for P2 and arginine/lysine for P1;
finally, alanine, valine, isoleucine, serine, and glycine were
entered for P1. The search resulted in the identification of
three extracellular cleavage sites on ASIC1 (Fig. 7A). Because
the matriptase catalytic domain is extracellular and matriptase
is activated after it reaches the cell surface (20), we ignored the
intracellular N and C termini of ASIC1 and ASIC2. The soft-
ware recognized one site (Lys-174) as a matriptase cleavage site
on the extracellular loop of ASIC2. However, the electrophysi-
ological and biochemical data showed no effect of matriptase
on ASIC2 function, and no matriptase-specific ASIC2 frag-
ments were detected, suggesting this site may not be accessible
to cleavage.
Alignment of the ASIC1 and ASIC2 amino acid sequences
with ClustalW shows the locations of the three matriptase
cleavage sites onASIC1, the equivalent sites onASIC2, and that
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the matriptase recognition sequences on ASIC1 are not con-
served on ASIC2 (Fig. 7A1). A schematic of the ASIC1-GFP,
GFP-ASIC1, and ASIC1-HA proteins indicating the three
cleavage sites, the fragments, and their sizes is shown in Fig.
7A2. The size estimates take into account the weight added by
potential glycosylations at Asn-368 and Asn-395 (28). For two
glycosylations, 5 kDa was added to the calculated size of a
peptide fragment (29).
We mutated the matriptase sites on the ASIC1-GFP con-
struct with site-directed mutagenesis, measured whole-cell
peak pH4.0 currents of themutantswith orwithoutmatriptase,
and detected the proteins with a GFP antibody. We chose the
oocyte expression system instead of CHO cells for the
mutagenesis experiments, because in oocytes we observed
cleavage of ASIC1, but not ASIC2, without the substantial
decrease in the expression of ASIC2 protein, which was caused
by matriptase in CHO cells.
Mutation of the first matriptase site to Ala (R145A) (referred
to as ASIC1 AKK) prevented the decrease in current observed
whenmatriptase was co-injectedwith the wild type ASIC1 (Fig.
7B). ASIC1 AKK-GFP was not cleaved by matriptase to the
same extent as wild type ASIC1; however, some fragments of
ASIC1 AKK-GFP were detected (Fig. 7C). The fragments cor-
respond to the same ones observed in wild type ASIC1-GFP,
with the exception that the biggest cleavage product (the one
observed right above 75 kDa, corresponding to cleavage at posi-
tion 145) was missing (Fig. 7C). The densitometry of the 100-
kDa band of ASIC1 AKK-GFP showed that this mutation pre-
vented the decrease in full-length ASIC1-GFP, which was
observed for the wild type ASIC1-GFP shown in Fig. 4B (Fig.
7C). Because the GFP tag is located in the C terminus of ASIC1,
and the size of the fragment from Arg-145 to the C terminus of
GFP would be 72 kDa, it was not surprising not to detect this
fragment when Arg-145 was changed to the noncleavable Ala
residue (Fig. 7, A1 and C). Arg-145 is the main trypsin cleavage
site on ASIC1, although some cleavage of ASIC1 R145A by
trypsin has also been observed (20).
Because the mutation of Arg-145 to Ala completely pre-
vented the effect of matriptase on ASIC1, we hypothesized that
this was the main site of ASIC1 cleavage bymatriptase and that
the other two sites (Lys-185 and Lys-384) were not as impor-
tant. To test this hypothesis, wemade anASIC1-GFP construct
with Lys-185 and Lys-384mutated to Ala (ASIC1 RAA). If Arg-
145 is the only site of matriptase cleavage, we would expect
matriptase to decrease the current of theASIC1RAA-GFP con-
struct similarly to thewild typeASIC1 and also to detect similar
cleavage products on Western blots. However, although
matriptase decreased the current of ASIC1 RAA-GFP by about
30%, this decrease was not statistically significant or compara-
ble with the much larger decrease of the wild type ASIC1 cur-
rent caused by matriptase (by about 70–90%) (Fig. 7C). Some
cleavage of ASIC1 RAA-GFP was observed with cleavage prod-
ucts at 75 kDa, in agreement with the location of the Arg-145
site. Another fainter, smaller fragment was also observed and it
could indicate further degradation of the fragment from the
Arg-145 to the C terminus of the ASIC1-GFP or cleavage at
another nonspecific site. The smaller cleavage products, which
could result from cleavage at the other two sites (Fig. 7A2), are
not present in the RAA construct, where Lys-185 and Lys-384
are changed to noncleavable amino acids (Fig. 7C). The densi-
tometry shows that unlike with the wild type ASIC1-GFP, there
is no decrease in the full-lengthASIC1RAA-GFP. These results
suggest that Arg-145 is a matriptase cleavage site and that Lys-
185 and Lys-384 are also important.
Mutation of all three matriptase cleavage sites to alanines
(R145A, K185A, and K384A; referred to as ASIC1 AAA) pre-
vented the effect of matriptase on ASIC1 current and also pre-
vented ASIC1 protein cleavage (Fig. 7C). Compared with the
effect of matriptase on the wild type ASIC1, the densitometry
shows that there is no decrease in the full-length ASIC1 AAA-
GFP protein. Some cleavage of ASIC1 AAA-GFP was observed
with matriptase in overexposed films (not shown). Not unlike
trypsin (16), matriptase might cleave at nonspecific sites (there
aremany additionalArg or Lys residues in the extracellular loop
near the matriptase sites). Alternatively, the minimal cleavage
observed for ASIC1 AAA-GFP could be the result of some
other unknown endogenous proteases that get activated by
matriptase in the oocyte expression system.
DISCUSSION
Matriptase is an epithelial cell surface serine protease that is
expressed in a variety of carcinomas and has been implicated in
themalignant progression of cancers (20). Althoughmatriptase
is expressed in many different epithelial tissues and organs,
matriptasemRNA has not been detected in normal brain tissue
(17, 27). In this study we show that matriptase is expressed in
GBM cells. The data show that matriptase mRNA is expressed
in glioma cell lines and in freshly excised tissues from GBM
and grade III glioma (anaplastic astrocytoma). Matriptase RNA
could not be detected in primary humannormal astrocytes or in
FIGURE 6. Matriptase cleaves ASIC1-GFP and GFP-ASIC1, but not ASIC2-GFP, in transfected CHO cells. A, dose response of increasing amounts of
matriptase DNA co-transfected in CHO cells with 2 g of ASIC1-GFP DNA. Transfected CHO cells were lysed 2 days post-transfection, and whole-cell lysates
were subjected to Western blot with a GFP antibody. The densitometry of the full-length ASIC1-GFP band shows a linear relationship between increasing
amounts of matriptase DNA and decreasing amounts of full-length ASIC1-GFP and no effect of the catalytically inactive matriptase S805A. Data in the
densitometry graph are means  S.E. B, CHO cells transfected with 2 g of ASIC1-GFP alone (control lanes) or plus 2 g of matriptase or S805A were lysed after
being left untreated or after treatment with the proteasome inhibitor MG132 (5 g/ml, for 5 h or overnight). The whole-cell lysates were subjected to Western
blot with GFP antibody. The amount of full-length ASIC1-GFP decreases when it is co-transfected with matriptase but not with the catalytically inactive
matriptase S805A. Two small fragments are barely detected in the untreated samples of the matriptase lane. In the samples treated with MG132, the signal of
the fragments in the matriptase lane (F1 and F2) is increased. There are no ASIC1-GFP fragments in ASIC1-GFP or ASIC1-GFP plus matriptase S805A in either the
untreated or the MG132-treated samples. Data in the densitometry graph are means  S.E. C, the same conditions apply as in B, with the exception that
GFP-ASIC1 (ASIC1 with an N-terminal GFP tag) was used instead. One fragment of GFP-ASIC1 is detected only in the matriptase lanes, and its intensity increases
with MG132 treatment. The densitometry data are means  S.E. D, the same conditions apply as in B and C, with the exception that ASIC2-GFP was used instead
and MG132 treatment was overnight. Even though matriptase decreases the full-length ASIC2-GFP, no ASIC2-GFP fragments appear in the matriptase lanes of
untreated or MG-132-treated samples, suggesting that matriptase does not cleave ASIC2-GFP. The densitometry data are means  S.E. of three separate
experiments.
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two different freshly excised astrogliosis tissues. Unlike the
mRNA,matriptase protein is present in humanprimary normal
astrocytes and in glioma cell lines, but its expression in normal
astrocytes is much lower compared with glioma cells. It is pos-
sible that the levels of matriptase RNA in the normal astrocytes
were too low to detect under our conditions.
The presence of matriptase protein suggests a role for this
protease in glioma. Some of the physiological matriptase sub-
strates (namely, urokinase plasminogen activator (uPA), hepa-
tocyte growth factor/scatter factor (HGF/SF), and protease
activated receptor-2 (PAR-2)) are associated with increased
proliferation and invasiveness of glioma (30). In addition, over-
expression of HAI-1, the cognate matriptase inhibitor, sup-
pressed the in vitro invasiveness of the U251 glioblastoma cell
line (24).
As a cell surface protease, matriptase is in an ideal position to
cleave the extracellular loops of ion channels. In the Xenopus
oocyte expression system, matriptase increased the activity of
ENaC (17, 18). ASICmodulation by proteases has been less
studied, butmost proteases that have been tested have an effect
on ASIC1 or ASIC1-containing heteromeric ASICs and no
effect on ASIC2 or ASIC3 (15). The goal of this study was to test
the hypothesis that matriptase can modulate ASIC1 function
through proteolytic cleavage. We used heterologous expression
systems and electrophysiological and biochemical approaches
to determine the effect of matriptase on the function of ASIC1
and also to determine if/where in the extracellular loop of
ASIC1 matriptase cleavage occurs.
Our data show that ASIC1 is a matriptase substrate in two
heterologous expression systems, Xenopus oocytes and CHO
cells, and that unlike its effect on ENaC, matriptase decreases
the function of ASIC1. This effect requires the catalytic activity
of matriptase and is associated with the presence of ASIC1
cleavage products. The putative matriptase cleavage sites on
ASIC1 areArg-145, Lys-185, and Lys-384. The crystal structure
of chicken ASIC1 and alignments of ASICs from different spe-
cies enabled us to locate these sites in the extracellular loop of
ASIC1, which resembles a clenched hand and contains a palm
(made of -strands), knuckle, finger, thumb (all made of -hel-
ices), and -ball. The thumb, -ball, and finger, along with the
palm of an adjacent subunit, form the acidic pocket or proton-
binding site of the channel (4). Arg-145 is located in the finger
domain, Lys-185 in the -ball, and Lys-384 between the palm
and knuckle domains. Because all three sites are located at or
close to the pH-sensing region (4), channels cleaved at these
sites are likely not functional, suggesting that the small current
measured in ASIC1  matriptase is probably due to a few non-
cleaved channels. In agreement with this idea, the data show
that the pH activation and PcTX-1 sensitivity of this current are
not different from that of noncleaved ASIC1.
The first matriptase cleavage site, Arg-145, was previously
characterized as a trypsin site (16). Similar to our results with
matriptase, the application of extracellular trypsin decreased
the peak acid-activated current of ASIC1 but had no effect on
ASIC2 (16). Themutagenesis experiments strongly suggest that
the effect of matriptase is direct, involving cleavage of ASIC1 in
several locations in the extracellular loop. However, because
some cleavage was observed in the ASIC1 AAA mutant, our
results do not rule out the possibility that matriptase cleaves
at adjacent arginines or lysines or that it activates another
endogenous protease, which could cleave at other nearby
sites. One such protease is prostasin. Matriptase co-localizes
with and activates prostasin, which has been shown to activate
ENaC (17, 18, 31). Therefore, the substrate recognition
motif for prostasin, which is (R/K)(H/K/R)X(R/K) (whereX is a
basic or hydrophobic amino acid) (32), and the ASIC1 amino
acid sequence were entered in the FindPatterns program in
SeqWeb version 3.1.2, Genetics Computer Group (University
of Alabama at Birmingham), to look for putative prostasin sites
on ASIC1. However, the search identified no prostasin sites on
ASIC1, suggesting that cleavage of ASIC1 by matriptase-acti-
vated prostasin is unlikely.
The ASIC1 cleavage fragments observed due to matriptase
correlate well with what would be expected from cleavage at
those three sites. Because many fragments were observed, it is
possible that not all the channels are cleaved at all three sites.
If that were the case, then the only size observed, for exam-
ple, in the ASIC1-GFP construct, would be the smallest frag-
ment still attached to GFP. This is the fragment from Lys-
384 of ASIC1 to the C terminus of GFP with a calculated size
of 40 kDa (Fig. 7A2). We do not know whether the ASIC1
fragments remain associated once cleaved by matriptase.
Because cleaved fragments of ENaC and ENaC remain
associated within the channel, it is possible that this is the
case for ASIC1 as well (11).
The cleavage of ASIC1 bymatriptase has implications for the
pathologies in which ASIC1 is involved. ASIC1 is mainly a neu-
ronal channel, and matriptase expression in neurons has not
FIGURE 7. Identification and confirmation of the matriptase sites on ASIC1. A1, alignment of the human ASIC1b (NM_001095) and human ASIC2b
(NM_001094) proteins showing the locations of the three matriptase cut sites on ASIC1 and the equivalent sites on ASIC2. All three locations are in the
extracellular loop; the N and C termini of ASIC1 and ASIC2 were ignored because matriptase catalytic domain is extracellular. The matriptase cut sites were
identified with software from Genetics Computer Group (University of Alabama at Birmingham) in which the information for positions P4, P3, P2, P1, and P1,
with P1 being the cut site, was entered manually (20). One matriptase site was identified by the software in the extracellular loop of ASIC2 at Lys-174, but
because no ASIC2 fragments were detected, it may not be accessible to cleavage. A2, the schematics of ASIC1-GFP, GFP-ASIC1, and ASIC1-HA are shown,
indicating the three matriptase sites in each protein and the sizes of the fragments expected from cleavage at these sites. The sizes take into account weight
added by potential glycosylations. Only the fragments that are attached to tags, and therefore could be detected by Western blots, are shown. *, potential
glycosylation sites (Asn-368 and Asn-395) (28) B, matriptase does not decrease the current of ASIC1 with Arg-145 mutated to Ala (R145A/K/K) or of the triple
mutant R145A/K185A/K384A (AAA). Matriptase only slightly decreases the current of the R/K185A/K384A mutant. Representative traces from each experiment
are shown. The normalized IpH4.0 are means  S.D. The numbers of oocytes are shown in parentheses and are from two to three different experiments. C, oocytes
were injected with 12 ng of ASIC1 AKK-GFP, ASIC1 RAA-GFP, or ASIC1 AAA-GFP with or without 12 ng of matriptase cRNA. The whole-cell lysates were subjected
to 12% SDS-PAGE and Western blot with a GFP antibody. Some cleavage products were detected for the ASIC1 AKK and ASIC1 RAA. For the ASIC1 AAA, in which
all three matriptase sites are mutated to alanines, no fragments were detected. The normalized densitometry of the full-length bands for ASIC1 AKK, ASIC1 RAA,
and ASIC1 AAA, with and without matriptase, shows that despite the presence of some fragments, there is no dramatic decrease in the full-length protein (in
contrast to the wild type ASIC1-GFP protein). The densitometry values are means  S.E.
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been reported; however, matriptase expressed by astrocytes
could possibly modulate ASIC1 in neurons. Matriptase could
modulate ASIC1 activity acting to decrease ASIC1 function
through proteolytic cleavage.
Thus far the regulation of ASIC1 by proteases has been
explored using heterologous expression systems (15, 16).We
report matriptase expression in glioblastoma cells, where
ASIC1 is also expressed (5–8). Although nothing is known
about the proteolytic cleavage of ASIC1 in glioma, the expres-
sion of both matriptase and ASIC1 in the same cell type makes
proteolytic cleavage of ASIC1 by matriptase in a nonheterolo-
gous system a realistic possibility.
Acknowledgments—The hASIC1b and hASIC2b constructs were a
kind gift of Dr. David Corey.Matriptase DNAwas a gift fromDr. C. Y.
Lin (Lombardi Cancer Center, Georgetown University Medical Cen-
ter). We thank Melissa McCarthy for technical assistance with cell
culture, Ian Thornell and Xiaofeng Hu for technical assistance with
Xenopus surgeries, Dr. Wanda Vila-Carriles for the ASIC2-HADNA,
and David Clark for assistance with fitting the pH activation data to
the Hill equation. We also thank Drs. Kevin Kirk, Mark Bevensee,
Niren Kapoor, and Yawar Qadri for helpful discussions and Brooke
Goodman for some of the RNA isolations.
REFERENCES
1. Wemmie, J. A., Price, M. P., and Welsh, M. J. (2006) Trends Neurosci. 29,
578–586
2. Kellenberger, S., and Schild, L. (2002) Physiol. Rev. 82, 735–767
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